
Loading, please wait...

Loading, please wait...

Antiresorptive therapies provide immense skeletal protection for postmenopausal osteoporosis, yet they carry an uncommon risk of medication-related osteonecrosis of the jaw. Clinicians now face an intriguing diagnostic puzzle regarding denosumab induced MRONJ emerging at sites with pre-existing radiopacities. Recently, researchers documented a 70-year-old female patient who received long-term denosumab therapy and subsequently developed necrosis in her posterior mandible. Interestingly, baseline cone-beam computed tomography imaging four years earlier demonstrated an asymptomatic, well-defined hyperdense lesion provisionally classified as a dense bone island. Over the four-year interval, this silent area transformed into an active infectious process. The patient eventually presented with pain, mucosal breakdown, and an active intraoral fistula. Follow-up volumetric imaging confirmed extensive cortical disruption, mandibular canal involvement, and frank sequestrum formation consistent with Stage 2 osteonecrosis. Histopathological evaluation after surgical debridement verified necrotic lamellar bone, bacterial colonization, and absence of vital osteocytes. Consequently, this remarkable case underscores how pre-existing sclerotic anomalies might complicate bone remodeling under potent antiresorptive suppression. Dental practitioners and endocrinologists must therefore maintain elevated vigilance when managing asymptomatic radiographic opacities in patients receiving receptor activator of nuclear factor-kappa B ligand inhibitors.
A dense bone island, also termed idiopathic osteosclerosis, represents a localized intraosseous radiopacity of developmental or reactive origin. Radiologists typically identify these lesions as incidental findings on routine panoramic radiographs or computed tomography scans. Furthermore, these benign entities most frequently arise within the premolar and molar regions of the mandible. Classic radiographic criteria describe a uniform, well-circumscribed radiopaque focus lacking any peripheral radiolucent halo. In addition, the surrounding cortex remains completely intact without expansion, periosteal reaction, or displacement of adjacent neurovascular structures. Histologically, these islands consist of thickened, compact lamellar bone that replaces normal trabecular architecture and marrow spaces. Because they lack active inflammation, clinicians traditionally regard them as harmless anatomical variants that require no therapeutic intervention. However, their altered microvascular network and compromised haversian canal distribution may limit localized perfusion. When clinicians administer powerful osteoclast inhibitors, the already reduced cellular turnover in sclerotic regions might plummet further. Consequently, focal bone renewal stalls during microtrauma or subclinical bacterial penetration. Thus, what appears as an innocuous bone island on baseline scans might harbor altered biological resilience under persistent antiresorptive drug exposure.
Denosumab acts as a fully human monoclonal antibody targeting the receptor activator of nuclear factor-kappa B ligand. By preventing RANKL from binding its receptor on osteoclast precursors, the drug profoundly suppresses osteoclastic differentiation and bone resorption. Consequently, cortical and trabecular mineral density rises significantly, protecting vulnerable patients against osteoporotic fractures. Nevertheless, prolonged suppression of physiological bone remodeling impairs the natural repair of everyday skeletal microdamage. Unlike bisphosphonates, denosumab does not bind permanently to hydroxyapatite crystals, yet its biological suppression remains robust during active administration cycles. When mucosal breaches occur, oral microbes readily invade the underlying hypovascular alveolar bone. Therefore, local immune responses falter, permitting opportunistic colonization and chronic osteomyelitis. In the presented case, denosumab induced MRONJ manifested after years of ongoing therapy without obvious preceding dental extractions. Clinicians observed classical Stage 2 disease features, notably an intractable purulent fistula and exposed bone. Moreover, the anatomical colocalization of necrosis with the pre-existing osteosclerosis raises critical pathophysiological questions. Although researchers cannot claim direct causality, severe inhibition of turnover within already hypovascular sclerotic bone likely accelerates ischemic necrosis under infectious pressure.
Cone-beam computed tomography provides superior three-dimensional diagnostic capability compared to standard two-dimensional planar imaging. Specifically, CBCT eliminates anatomical superimposition, allowing clinicians to evaluate fine trabecular architecture and subtle cortical erosions. In this case, longitudinal imaging provided an invaluable retrospective timeline of jaw destruction. Initially, the baseline volumetric scan demonstrated an isolated, hyperdense focus in the posterior mandible with well-defined margins. Four years later, repeat computed tomography uncovered dramatic structural degeneration at the identical anatomical coordinate. The lesion exhibited a prominent mixed osteolytic and osteosclerotic pattern accompanied by ragged margins and cortical perforation. Furthermore, the imaging clearly visualized mandibular canal involvement, explaining the patient's localized discomfort and neurosensory vulnerability. Most importantly, three-dimensional reconstruction pinpointed dense bone sequestra separating from viable surrounding host bone. Standard periapical or panoramic radiographs routinely underestimate the true spatial boundaries of medication-related necrosis. In contrast, volumetric imaging delineates the complete margin of compromised bone, which proves indispensable for subsequent surgical planning. Clinicians can accurately determine safe resection margins while protecting adjacent vital nerves and vessels. Thus, serial volumetric tomography remains an indispensable imaging modality for monitoring suspected jaw lesions.
Managing established medication-related osteonecrosis demands an individualized, stage-specific strategy. According to current international guidelines, Stage 2 necrosis requires comprehensive medical and surgical intervention. Initially, clinicians prescribe targeted antimicrobial therapy and antiseptic oral rinses to control active superficial infection and relieve mucosal inflammation. However, conservative measures rarely eliminate extensive sequestra embedded within deep mandibular bone. Therefore, surgeons performed thorough surgical debridement and sequestrectomy under copious irrigation. They meticulously resected nonviable cortical margins until reaching freely bleeding bone boundaries. Histopathological examination subsequently confirmed nonviable lamellar bone containing empty lacunae and dense bacterial biofilms. In addition, the surgical team smoothed sharp bony prominences to facilitate primary tension-free soft tissue closure. Medical providers must also coordinate closely regarding antiresorptive dosing schedules. While drug holidays for denosumab carry potential risks of rebound vertebral fractures, managing refractory bone infection may necessitate temporary therapeutic pauses. Postoperatively, multidisciplinary teams must implement rigorous hygiene maintenance and routine radiographic surveillance. Clinicians should carefully evaluate any persisting radiographic opacities before performing elective dentoalveolar surgery. Ultimately, proactive collaboration between dental surgeons and prescribing physicians optimizes both skeletal integrity and maxillofacial health.
Current scientific evidence does not show a direct causal relationship between dense bone islands and osteonecrosis. Although dense bone islands exhibit dense hypovascular architecture, they represent benign anatomical variants. However, when patients receive potent antiresorptive drugs like denosumab, localized bone turnover drops dramatically. If bacterial infection or minor microtrauma penetrates this hypovascular site, tissue repair falters rapidly. Consequently, necrosis may develop coincidentally or secondary to impaired regional remodeling rather than direct lesion transformation.
Cone-beam computed tomography provides high-resolution, three-dimensional diagnostic reconstructions without tissue distortion or anatomical superimposition. While conventional panoramic radiographs often miss early cortical breaches, CBCT accurately detects subtle trabecular changes, periosteal reactions, and early sequestrum formation. Furthermore, it visualizes the true three-dimensional margins of necrotic bone relative to adjacent anatomical landmarks, including the mandibular canal and maxillary sinus. Therefore, clinicians rely on volumetric scans to guide staging, evaluate lesion progression, and execute precise surgical debridement.
Before initiating denosumab therapy, patients must undergo a meticulous oral examination and complete all necessary invasive dental procedures. Prescribers should establish clear medical-dental communication to educate patients on rigorous plaque control and early symptoms of bone exposure. Additionally, clinicians should avoid elective extractions during ongoing antiresorptive therapy, opting for conservative endodontic treatments whenever feasible. If invasive oral surgery becomes unavoidable, surgeons must employ minimally traumatic techniques, primary soft tissue closure, and close postoperative clinical monitoring.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


This case report examines the longitudinal CBCT evolution of Stage 2 MRONJ in a 70-year-old woman on denosumab at the site of a pre-existing mandibular dense bone island. It emphasizes the radiographic features, differential diagnosis, and multidisciplinary strategies required for high-risk bone lesions.
Today

Microplastic contamination in seafood presents emerging public health and gastrointestinal concerns. Learn how synthetic polymers from marine gastropods affect human health, gut integrity, and dietary counseling strategies.
Today

Estetrol (E4), a native fetal estrogen, offers a unique tissue-selective profile with minimal hepatic impact and lower thrombotic risk. This review highlights its clinical use in oral contraception, menopausal symptom management, and emerging applications across oncology and neurology.
Today

A systematic review and component network meta-analysis evaluated the incremental benefits of drug classes in HFmrEF and HFpEF. SGLT-2 inhibitors and MRAs provided the most robust reductions in heart failure hospitalizations, while mortality benefits remained elusive across all investigated drug classes.
Today

A landmark study reveals that physiologic subtypes of gestational glucose intolerance, including insulin resistance and insulin deficiency, independently raise long-term risks of maternal prediabetes and diabetes, underscoring the urgent need for structured postpartum surveillance.
Today